217 related articles for article (PubMed ID: 1586374)
41. Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
Hutt V; Theodor R; Pabst G; Bonn R; Fritschi E; Jaeger H
J Clin Pharmacol; 1992 Jun; 32(6):553-7. PubMed ID: 1634643
[TBL] [Abstract][Full Text] [Related]
42. Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.
Schneider W; Menke G; Heidemann R; Satter P; Kaltenbach M; Rietbrock N
Eur J Clin Pharmacol; 1990; 38(2):145-7. PubMed ID: 2338111
[TBL] [Abstract][Full Text] [Related]
43. Clinical chronopharmacology of oral nitrates.
Lemmer B; Scheidel B; Stenzhorn G; Blume H; Lenhard G; Grether D; Renczes J; Becker HJ
Z Kardiol; 1989; 78 Suppl 2():61-3; discussion 64-7. PubMed ID: 2588762
[TBL] [Abstract][Full Text] [Related]
44. Effects of isosorbide dinitrate spray on central hemodynamics. Comparison with sublingual glyceryl trinitrate and isosorbide dinitrate.
Saito M; Fukami K; Sumiyoshi T; Haze K; Hiramori K
Arzneimittelforschung; 1984; 34(6):707-9. PubMed ID: 6435644
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the time to onset of action on myocardial ischaemia following intravenous administration of isosorbide dinitrate and 5-isosorbide mononitrate in Chinese patients.
Wu ZG; Li JN; Fan M; Shang YK; Zhang YW; Bai J; Ding R; Cheng JM; Liang C
Arzneimittelforschung; 2004; 54(5):275-9. PubMed ID: 15212189
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
Fung HL
Am Heart J; 1985 Jul; 110(1 Pt 2):213-6. PubMed ID: 4013997
[TBL] [Abstract][Full Text] [Related]
47. Comparative hemodynamic study of IS-5-MN and ISDN in man--which are equieffective doses?
Vogt A; Bernhardt S; Schwarck H; Stroh E; Kreuzer H
Z Kardiol; 1983; 72 Suppl 3():182-4. PubMed ID: 6666220
[TBL] [Abstract][Full Text] [Related]
48. Differences in the production of methemoglobin during high-dose treatment with isosorbide dinitrate or isosorbide 5-mononitrate.
Schneider W; Stahl B; Kaltenbach M; Bussmann WD
Arzneimittelforschung; 1984; 34(12):1779-82. PubMed ID: 6543314
[TBL] [Abstract][Full Text] [Related]
49. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.
Abshagen U; Betzien G; Endele R; Kaufmann B
Eur J Clin Pharmacol; 1981; 20(4):269-75. PubMed ID: 7308280
[TBL] [Abstract][Full Text] [Related]
51. Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.
Morrison RA; Wiegand UW; Jähnchen E; Höhmann D; Bechtold H; Meinertz T; Fung HL
Clin Pharmacol Ther; 1983 Jun; 33(6):747-56. PubMed ID: 6851405
[TBL] [Abstract][Full Text] [Related]
52. Chronopharmacology of oral nitrates in healthy subjects.
Scheidel B; Lemmer B
Chronobiol Int; 1991; 8(5):409-19. PubMed ID: 1818789
[TBL] [Abstract][Full Text] [Related]
53. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Vree TB; Dammers E; Valducci R
Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
[TBL] [Abstract][Full Text] [Related]
54. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
Döring G
J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
[TBL] [Abstract][Full Text] [Related]
55. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)].
Kogi K; Chida S; Kimura T; Saito T
Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370
[TBL] [Abstract][Full Text] [Related]
56. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system.
Gabiga H; Cal K; Janicki S
Int J Pharm; 2000 Apr; 199(1):1-6. PubMed ID: 10794921
[TBL] [Abstract][Full Text] [Related]
57. Effects of disease, route of administration, cigarette smoking, food intake on the pharmacokinetics and circulatory effects of isosorbide dinitrate.
Fung HL; Ruggirello D; Stone JA; Parker JO
Z Kardiol; 1983; 72 Suppl 3():5-10. PubMed ID: 6666234
[TBL] [Abstract][Full Text] [Related]
58. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
Thomson AH; Miller SH; Green ST; Whiting B
Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048
[TBL] [Abstract][Full Text] [Related]
59. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man.
Abshagen U; Spörl-Radun S
Eur J Clin Pharmacol; 1981; 19(6):423-9. PubMed ID: 7250175
[TBL] [Abstract][Full Text] [Related]
60. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
Halkin H; Almog S; Friedman E
Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
